Get started
Author

Konstantin Penkov

Observed names: K. D. Penkov, K. Penkov, K.D. Penkov
Institution: Russian Railways
Observed institutions: Cleveland Clinic, Memorial Sloan Kettering Cancer Center, Russian Railways, Institut Gustave Roussy, The Netherlands Cancer Institute, Centre Léon Bérard, Institute of Oncology NN Petrov
ORCID: 0009-0005-8998-3107
Observed ORCID: 0009-0005-8998-3107
OpenAlex ID: A5017206712
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
2019 · Robert J. Motzer, Konstantin Penkov, et al. · New England Journal of Medicine · 2,558
PDF
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
2020 · Robert J. Motzer, Paul B. Robbins, et al. · Nature Medicine · 528
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer
2022 · Ying Cheng, Liang Han, et al. · JAMA · 510
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
2023 · Kim N. Chi, Dana Rathkopf, et al. · Journal of Clinical Oncology · 381
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial
2022 · Miranda Gogishvili, Tamar Melkadze, et al. · Nature Medicine · 333
PDF
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study
2021 · Fiona Blackhall, Kevin Jao, et al. · Journal of Thoracic Oncology · 293
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK -Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study
2022 · Benjamin J. Solomon, Todd M. Bauer, et al. · Journal of Clinical Oncology · 146
PDF
Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial
2023 · Tamta Makharadze, Miranda Gogishvili, et al. · Journal of Thoracic Oncology · 124
PDF
Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
2024 · Yen-Shen Lu, Eznal Izwadi Bin Mohd Mahidin, et al. · Journal of Clinical Oncology · 104
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial
2023 · A.O. Siefker-Radtke, N. Matsubara, et al. · Annals of Oncology · 96
PDF
Biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A+Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).
2019 · Toni K. Choueiri, Laurence Albiges, et al. · Journal of Clinical Oncology · 96
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study
2021 · Lauren Averett Byers, Dmitry Bentsion, et al. · Clinical Cancer Research · 77
PDF
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial
2024 · T.K. Choueiri, K. Penkov, et al. · Annals of Oncology · 75
PDF
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
2023 · J.B.A.G. Haanen, J. Larkin, et al. · ESMO Open · 63
PDF
Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations
2023 · Alessandra Bearz, Jean-François Martini, et al. · Journal of Thoracic Oncology · 55
PDF
INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025 · Jérôme Fayette, Lisa Licitra, et al. · Clinical Cancer Research · 37
PDF
Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)
2024 · Nizar M. Tannir, Maria Nirvana Formiga, et al. · Journal of Clinical Oncology · 36
JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)
2018 · R.J. Motzer, K. Penkov, et al. · Annals of Oncology · 34
PDF
CREST: phase III study of sasanlimab and Bacillus Calmette-Guérin for patients with Bacillus Calmette-Guérin-naïve high-risk non-muscle-invasive bladder cancer
2024 · Gary D Steinberg, Neal D Shore, et al. · Future Oncology · 33
Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial.
2024 · Robert J. Motzer, Konstantin Penkov, et al. · Journal of Clinical Oncology · 28
PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma (RCC).
2020 · Nizar M. Tannir, Neeraj Agarwal, et al. · Journal of Clinical Oncology · 20
Quality of life with cemiplimab plus chemotherapy for first‐line treatment of advanced non–small cell lung cancer: Patient‐reported outcomes from phase 3 EMPOWER‐Lung 3
2023 · Tamta Makharadze, Ruben G. W. Quek, et al. · Cancer · 19
PDF
LBA51 EMPOWER-Lung 3: Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC)
2021 · M. Gogishvili, T. Melkadze, et al. · Annals of Oncology · 19
PDF
Efficacy of avelumab + axitinib (A + Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.
2021 · John B. A. G. Haanen, James Larkin, et al. · Journal of Clinical Oncology · 18
Phase 1 trial of mevrometostat (PF-06821497), a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in castration-resistant prostate cancer (CRPC).
2024 · Michael Thomas Schweizer, Konstantin Penkov, et al. · Journal of Clinical Oncology · 16
Works count: 77
Citation count: 5,957
H-index: 22
I10-index: 30
Year
Topic
Type